#mabs — Public Fediverse posts

Porcine #influenza #mAbs to #H3, #H5, and #H7 hemagglutinins recognize H3 egg adapted site and target the HA stem, https://etidiohnew.blogspot.com/2026/03/porcine-influenza-mabs-to-h3-h5-and-h7.html

🧬 One amino acid to stabilize them all — myth or molecular reality?

🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045

📚 CSBJ: https://www.csbj.org/

#MonoclonalAntibodies #mAbs #Immunology #ComputationalBiology #MolecularDynamics #Bioinformatics #ProteinStability #StructuralBiology

@MaxionTherapeutics, not on #Bluesky, announces the completion of their $72M Series A. #biotech #mAbs #antibodies #channels #DrugDiscovery #Loxbridge

RE: https://bsky.app/profile/did:plc:oxh2lmowuusxjqn4f4usyjk5/post/3lkkzp4ocn22q

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 {#mAbs} in Healthy #Adults for #Prevention of #Influenza A Illness (PENINSULA), Clin Infect Dis.: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae368/7717845?login=false

VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

[Articles] Effect of anti- #Ebola virus #mAbs on endogenous #antibody production in #survivors of #EVD in the #DRC: an observational cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00552-2/fulltext?rss=yes

#Antigenicity and #receptor affinity of #SARS-CoV-2 #BA286 #spike, https://www.nature.com/articles/s41586-023-06750-w #research #variants #VOI #vaccines #mAbs

''Here, we demonstrate analogous humoral #antigen recognition between both MPXV-infected or #Smallpox-vaccinated individuals, with binding to diverse yet core set of #poxvirus antigens, providing opportunities for future vaccine (e.g., #mRNA) and therapeutic (e.g., #mAbs) design.''

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

@failedLyndonLaRouchite
Absolutely. #mAbs are a net plus, certainly for the person.

@rbreich Other major issues at work are: 1. Easy $$ on existing revenue streams protected by gov't rules (FDA, etc) that limit competition; 2. Little C-level $$ incentive to pursue risky research projects (why risk bonus $$?). This has major downstream consequences to world-wide health as evidenced by virtually no #R&D on new #antibiotics & major focus on #diseases that can be addressed by #monoclonal #antibodies, which cost much less for big Pharma to develop. Profit margins on #mAbs are HUGE.

The best thing about being a #Pharmacometrician (IMHO) is that you never stop learning, and every job is different. Right now I work a lot in #Immunooncology, the use of monocolonal antibodies (#mAbs) for treating #Cancer. mAbs have their own interesting set of complexities. (Well, they're interesting after we've figured them out. Before that that they're just maddening.)